Literature DB >> 17072337

Regulation of survivin expression by IGF-1/mTOR signaling.

V Vaira1, C W Lee, H L Goel, S Bosari, L R Languino, D C Altieri.   

Abstract

Survivin is a dual regulator of cell proliferation and cell viability overexpressed in most human tumors. Although strategies to lower survivin levels have been pursued for rational cancer therapy, the molecular circuitries controlling survivin expression in tumors have not been completely elucidated. Here, we show that stimulation with insulin-like growth factor-1 (IGF-1) results in increased survivin expression in prostate cancer cells. This response is independent of de novo gene transcription, changes in mRNA expression or modifications of survivin protein stability. Instead, IGF-1 induced persistence and translation of a pool of survivin mRNA, in a reaction abolished by the mTOR (mammalian target of rapamycin) inhibitor, rapamycin. Forced expression of the mTOR target p70S6K1 reproduced the increase in survivin expression in prostate cancer cells, whereas acute ablation of endogenous p70S6K1 by small interfering RNA downregulated survivin levels. Rapamycin, alone or in combination with suboptimal concentrations of taxol reduced survivin protein levels, and decreased viability of prostate cancer cells. Therefore, IGF-1/mTOR signaling elevates survivin in prostate cancer cells via rapid changes in mRNA translation. Antagonists of this pathway may be beneficial to lower an antiapoptotic threshold maintained by survivin in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072337     DOI: 10.1038/sj.onc.1210094

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  79 in total

1.  DARPP-32 is required for MAPK/ERK signaling in thyroid cells.

Authors:  Ana Chocarro-Calvo; Miguel A Zaballos; Pilar Santisteban; Custodia García-Jiménez
Journal:  Mol Endocrinol       Date:  2012-02-02

2.  The RNA-binding protein CUG-BP1 increases survivin expression in oesophageal cancer cells through enhanced mRNA stability.

Authors:  Elizabeth T Chang; James M Donahue; Lan Xiao; Yuhong Cui; Jaladanki N Rao; Douglas J Turner; William S Twaddell; Jian-Ying Wang; Richard J Battafarano
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

Review 3.  Mammalian target of rapamycin: a central node of complex signaling cascades.

Authors:  Yoh Dobashi; Yasutaka Watanabe; Chihiro Miwa; Sakae Suzuki; Shinichiro Koyama
Journal:  Int J Clin Exp Pathol       Date:  2011-06-14

4.  Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1α induction.

Authors:  Bin Chen; Sun Yuping; Jian Ni
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

5.  Emerging therapies in pancreas cancer.

Authors:  Adam Kotowski; Wen W Ma
Journal:  J Gastrointest Oncol       Date:  2011-06

6.  Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Authors:  Neeraj Kapur; Hina Mir; Guru P Sonpavde; Sanjay Jain; Sejong Bae; James W Lillard; Shailesh Singh
Journal:  Cancer Lett       Date:  2019-04-08       Impact factor: 8.679

7.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

8.  mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.

Authors:  Liqun Zhao; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

9.  Caspase 2-mediated tumor suppression involves survivin gene silencing.

Authors:  M Guha; F Xia; C M Raskett; D C Altieri
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

10.  IGF-IR-dependent expression of Survivin is required for T-antigen-mediated protection from apoptosis and proliferation of neural progenitors.

Authors:  E Gualco; K Urbanska; G Perez-Liz; T Sweet; F Peruzzi; K Reiss; L Del Valle
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.